不同剂量瑞舒伐他汀钙治疗老年稳定性冠心病患者的临床效果  

Clinical effect of different doses of rosuvastatin calcium in the treatment of elderly patients with stable coronary artery disease

作　　者：张向红 ZHANG Xianghong(Xi'an Daxing Hospital,Xi'an 710002,China)

机构地区：[1]西安大兴医院,陕西西安710002

出　　处：《临床医学研究与实践》2025年第8期62-65,共4页Clinical Research and Practice

摘　　要：目的探讨不同剂量瑞舒伐他汀钙治疗老年稳定性冠心病(SCAD)患者的临床效果。方法选取2021年12月至2022年12月西安大兴医院收治的100例老年SCAD患者作为研究对象,根据瑞舒伐他汀钙使用剂量将其分为小剂量组和大剂量组,每组50例。小剂量组给予小剂量瑞舒伐他汀钙治疗,大剂量组给予大剂量瑞舒伐他汀钙治疗。比较两组的临床效果。结果大剂量组的治疗总有效率高于小剂量组(P<0.05)。治疗后,大剂量组的左心室射血分数(LVEF)大于小剂量组,左心室收缩末期内径(LVESD)、左心室收缩末期容积(LVESV)及左心室舒张末期容积(LVEDV)小于小剂量组(P<0.05)。治疗后,大剂量组的N-末端B型脑钠肽前体(NT-proBNP)、心肌肌钙蛋白T(cTnT)、可溶性ST2蛋白(sST2)、乳酸(LA)及心型脂肪酸结合蛋白(H-FABP)水平低于小剂量组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论相较于小剂量,大剂量瑞舒伐他汀钙治疗老年SCAD患者的效果更为显著,能够快速改善心功能,降低心肌标志物水平,且不会增加不良反应发生率,值得临床应用及推广。Objective To investigate the clinical effect of different doses of rosuvastatin calcium in the treatment of elderly patients with stable coronary artery disease(SCAD).Methods A total of 100 elderly patients with SCAD admitted in Xi'an Daxing Hospital from December 2021 to December 2022 were selected as the research objects.According to the dose of rosuvastatin calcium,the patients were divided into low-dose group and high-dose group,with 50 cases in each group.The low-dose group was treated with low-dose rosuvastatin calcium,and the high-dose group was treated with high-dose rosuvastatin calcium.The clinical effects of the two groups were compared.Results The total effective rate of treatment in the high-dose group was higher than that in the low-dose group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)in the high-dose group was greater than that in the low-dose group,and the left ventricular end-systolic diameter(LVESD),left ventricular end-systolic volume(LVESV)and left ventricular end-diastolic volume(LVEDV)were smaller than those in the low-dose group(P<0.05).After treatment,the levels of N-terminal pro-B-type natriuretic peptide(NT-proBNP),cardiac troponin T(cTnT),soluble ST2 protein(sST2),lactic acid(LA)and heart-type fatty acid-binding protein(H-FABP)in the high-dose group were lower than those in the low-dose group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with low-dose,high-dose rosuvastatin calcium is more effective in the treatment of elderly patients with SCAD,which can quickly improve cardiac function,reduce the levels of myocardial markers,and will not increase the incidence of adverse reactions.It is worthy of clinical application and promotion.

关 键 词：瑞舒伐他汀钙 老年 稳定性冠心病 不良反应 

分 类 号：R541.4[医药卫生—心血管疾病]